Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting.

[1]  W. Chapman,et al.  Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States. , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[2]  M. Schnitzler,et al.  Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. , 2020, Kidney360.

[3]  J. Friedewald,et al.  Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. , 2020, Journal of the American Society of Nephrology : JASN.

[4]  C. Quintini,et al.  Hepatitis C Virus NAT‐Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus–Negative Recipients: A Real‐World Experience , 2020, Hepatology.

[5]  R. Sterling,et al.  Ultra‐short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  J. Lindenfeld,et al.  Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C. , 2019, JAMA cardiology.

[7]  B. Tanriover,et al.  Short‐term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct‐acting antivirals , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  M. Molnar,et al.  Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: Single center experience , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  M. Chattergoon,et al.  Lessons from the real world: HCV‐infected donor kidney transplantation as standard practice , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[11]  Snehal R. Patel,et al.  Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  T. Cotter,et al.  Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)‐Viremic Donors Into HCV‐Negative Recipients: Outcomes Following Liver Transplant of HCV‐Viremic Donors , 2019, Hepatology.

[13]  R. Hasz,et al.  Transplanting hepatitis C virus–infected hearts into uninfected recipients: A single‐arm trial , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  R. Sterling,et al.  Cost‐effectiveness of hepatitis C–positive donor kidney transplantation for hepatitis C–negative recipients with concomitant direct‐acting antiviral therapy , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  R. Hasz,et al.  Twelve-Month Outcomes After Transplant of Hepatitis CInfected Kidneys Into Uninfected Recipients , 2018, Annals of Internal Medicine.

[16]  S. Klarenbach,et al.  Cost‐effectiveness of using kidneys from hepatitis C nucleic acid test–positive donors for transplantation in hepatitis C–negative recipients , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  D. Segev,et al.  Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C VirusInfected Donors to Noninfected Recipients , 2018, Annals of Internal Medicine.

[18]  T. Hassanein,et al.  Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. , 2017, Journal of hepatology.

[19]  R. Hasz,et al.  Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. , 2017, The New England journal of medicine.

[20]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[21]  M. Ciarleglio,et al.  Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade , 2015, PloS one.

[22]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[23]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[24]  E. Tuzcu,et al.  Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.